Organon Reports Results for the Second Quarter Ended June 30, 2022
Organon & Co. (OGN)
Company Research
Source: Business Wire
Second quarter 2022 revenues of $1,585 millionSecond quarter diluted earnings per share from continuing operations of $0.92 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.25Both reported and non-GAAP adjusted diluted earnings per share include a negative impact of $0.30 for acquired in-process research and development (IPR&D) and milestonesAdjusted EBITDA of $512 million, inclusive of $97 million of acquired IPR&D and milestonesBoard of Directors declares quarterly dividend of $0.28 per shareFull year 2022 financial guidance ranges updated:Revenues range narrowed to $6.1 billion to $6.3 billion, and reflects persisting foreign currency headwindsAdjusted EBITDA margin range now 32%-34% to incorporate acquired IPR&D and milestone expenses from recent business development JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (the “company”), today announced its results for the second quarter ended June 30, 2022."During the second quarter, Organon d
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- Organon (OGN) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]Yahoo! Finance
- Why the Market Dipped But Organon (OGN) Gained Today [Yahoo! Finance]Yahoo! Finance
- Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024Business Wire
- Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary EndpointsBusiness Wire
OGN
Earnings
- 2/15/24 - Beat
OGN
Sec Filings
- 4/16/24 - Form 4
- 4/3/24 - Form 4
- 4/3/24 - Form 4
- OGN's page on the SEC website